{"fetched":"2026-09-09","previousFetched":"2026-09-06","keepDays":90,"changes":[{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"primary-completion","from":"2027-02","to":"2026-09-04"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"primary-completion","from":"2026-09","to":"2025-08-11"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT03803553","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","phases":["PHASE3"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"relatlimab-nivolumab","nct":"NCT04080804","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","phases":["PHASE2"],"sponsor":"Dan Zandberg","primaryCompletion":"2026-04-13","kind":"primary-completion","from":"2027-10-01","to":"2026-04-13"},{"detected":"2026-09-09","drugId":"brentuximab-vedotin","nct":"NCT05039073","title":"Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2027-11-30","kind":"primary-completion","from":"2026-11-30","to":"2027-11-30"},{"detected":"2026-09-09","drugId":"autogene-cevumeran","nct":"NCT05968326","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","phases":["PHASE2"],"sponsor":"Genentech, Inc.","primaryCompletion":"2031-01-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT06578559","title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2026-05-12","kind":"primary-completion","from":"2026-08-01","to":"2026-05-12"},{"detected":"2026-09-09","drugId":"lutathera","nct":"NCT06955169","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","phases":["PHASE2"],"sponsor":"RTOG Foundation, Inc.","primaryCompletion":"2029-08","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"disitamab-vedotin","nct":"NCT06966453","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-10-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","phases":["PHASE3"],"sponsor":"Amgen","primaryCompletion":"2029-01-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"primary-completion","from":"2026-10-18","to":"2027-05-18"}]}